

CLINICAL FEATURES AND PROGNOSTIC OUTCOMES OF YOUNG CANCER PATIENTS: A RETROSPECTIVE STUDY

X.-K. WANG¹, Y. WU², M.-H. ZHOU³

• • •

¹Department of Radiology, the Fourth Medical Center, Chinese PLA General Hospital, Beijing, China

²Department of General Practice, the Fourth Medical Center, Chinese PLA General, Beijing, China

³Department 4th of Geriatric Health Care, the Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China

X.-K. Wang and Y. Wu contributed equally to this work.

CORRESPONDING AUTHOR

Min-hang Zhou, MD; e-mail: zhou_minhang@163.com

ABSTRACT – Objective: This study aimed to identify the clinical and prognostic characteristics of young cancer patients who were admitted to our hospital over the past two years.

Patients and Methods: The clinical features of young cancer patients who aged 18-45 years and were diagnosed in our hospital between January 2021 and December 2022, were retrospectively analyzed. The log-rank test was employed to compare the survival rates among different groups. The prognostic factors were assessed by the multivariate Cox regression model.

Results: A total of 620 cancer patients who aged 18-45 years were included. Notably, 260 (41.9%) patients were male and 360 (58.1%) were female. The median age was 38 (range, 18-45) years. The most common cancer types were thyroid cancer (182, 29.4%), non-small cell lung cancer (106, 17.1%), and soft tissue sarcoma (88, 14.2%). The median follow-up time was 18.5 (range, 3.4-29.4) months. The median overall survival was not achieved across different groups. The 2-year survival rate of all patients was 96.7%. Patients with distant metastases had worse survival than those without metastases (2-year survival rate, 84.0% vs. 99.4%, $p = 0.000$). Furthermore, multivariate analysis revealed that metastasis was an independent adverse prognostic factor for survival (hazard ratio 9.8, $p = 0.000$). A total of 17 cancer patients died, including nine patients with gastric cancer, three patients with colorectal cancer, three patients with hepatocellular carcinoma, one patient with pancreatic cancer, and one patient with glioma.

Conclusions: Metastasis was noted as an independent unfavorable prognostic factor for survival. Regular screening and timely diagnosis before metastasis are crucial to the therapy of young cancer patients.

KEYWORDS: Young cancer patients, Survival outcomes, Prognostic factors.

INTRODUCTION

Young patients diagnosed with malignant tumors should be recognized as a unique age group due to their distinct biology, epidemiology, and clinical outcomes¹⁻³. With advances in diagnosis and treatment, the overall survival (OS) of young cancer patients has prolonged, while some young cancer patients'



prognosis has remained unchanged for decades^{4,5}. In contrast to the older population, except for high-risk cases due to genetic or environmental factors, there is currently no effective screening method for young cases⁶⁻⁸. In addition, young cancer patients are inclined to overlook their symptoms, which may result in the delayed diagnosis and treatment⁹.

In all cancer patients, types of cancer with the highest incidence rates include breast cancer, prostate cancer, lung cancer, and colorectal cancer¹⁰. Compared with the general population, young cancer patients have a unique and significantly different cancer spectrum. In the United States, thyroid cancer, breast cancer and melanoma are the most common tumors among young cancer patients¹¹. However, little is known regarding the features of Chinese young cancer patients, including clinicopathological characteristics, OS, and prognostic factors. Therefore, the present study aimed to assess young cancer patients' clinicopathological features and prognosis.

PATIENTS AND METHODS

Patients

A retrospective study was conducted on young cancer patients who aged 18-45 years and were diagnosed in our hospital between January 2021 and December 2022. All diagnoses of cancer patients were identified by histopathology. Patients with hematological malignancies were excluded. A total of 620 cancer patients with complete clinical and follow-up data were enrolled in this study.

Methods

The collected data on each patient included demographics, Eastern Cooperative Oncology Group performance status (ECOG PS), types of cancer, antitumor therapies, the presence of metastasis, and survival time. This study was approved by the institutional review board of Chinese PLA General Hospital. Written informed consent was not required because of retrospective design and anonymous data. The research was conducted in accordance with the Declaration of Helsinki as revised in 2013.

Statistical analysis

Categorical variables were described as number with percentage, and continuous variables were summarized as median with range. The Kaplan-Meier method was utilized to OS and two-year survival rate with the SPSS 24.0 software (IBM, Armonk, NY, USA). The log-rank test was used to compare the survival rate among different groups. OS was defined as the time from the date of cancer diagnosis to the date of death or the last follow-up (May 2023). The multivariate Cox regression models were employed to identify the prognostic factors for OS. A p -value < 0.05 was considered statistically significant.

RESULTS

Patients' characteristics

A total of 620 cancer patients who aged 18-45 years were included in this study. Patients' demographic and clinical features are presented in Table 1. Notably, 260 (41.9%) patients were male and 360 (58.1%) were female. The median age was 38 (range, 18-45) years. The ECOG PS of all patients were < 2, with 0 in 359 (57.9%) patients and 1 in 261 (42.1%) patients, respectively. There were 97 patients with distant metastasis. As of May 2023, a total of 17 (2.7%) patients have passed away.

The top five cancer types with the highest incidence rates among all patients are listed in Table 2. In all 620 patients, the most common cancer types were thyroid cancer (182, 29.4%), non-small cell lung cancer (NSCLC, 106, 17.1%), and soft tissue sarcoma (88, 14.2%). In 260 male cancer patients, the most frequent cancer types were soft tissue sarcoma (61, 23.5%), thyroid cancer (52, 20.0%), and NSCLC (38, 14.6%). In 360 female cancer patients, the most common cancer types were thyroid cancer (130, 36.1%), NSCLC (68, 18.9%), breast cancer (58, 16.1%).

Table 1. Clinical characteristics of young cancer patients.

Characteristic	Total (%)
All	620 (100)
Gender	
Male	260 (41.9)
Female	360 (58.1)
Age (years)	
Range	18-45
Median	38
ECOG	
0	359 (57.9)
1	261 (42.1)
Metastasis	
No	523 (84.4)
Yes	97 (15.6)
Survival state	
Alive	603 (97.3)
Dead	17 (2.7)

Abbreviation - ECOG: Eastern Cooperative Oncology Group.

Table 2. Top five types of cancer in young cancer patients.

Type of cancer	Total n=620 (%)	Types of cancer	Male n=260 (%)	Types of cancer	Female n=360 (%)
Thyroid cancer	182 (29.4)	Soft tissue sarcoma	61(23.5)	Thyroid cancer	130 (36.1)
Non-small cell lung cancer	106 (17.1)	Thyroid cancer	52 (20.0)	Non-small cell lung cancer	68 (18.9)
Soft tissue sarcoma	88 (14.2)	Non-small cell lung cancer	38 (14.6)	Breast cancer	58 (16.1)
Breast cancer	59 (9.5)	Colorectal cancer	23 (8.8)	Soft tissue sarcoma	27 (7.5)
Colorectal cancer	40 (6.5)	Hepatocellular carcinoma	20 (7.7)	Colorectal cancer	17 (4.7)

Survival and prognostic factors of OS

The median follow-up time was 18.5 (range, 3.4-29.4) months. The median OS was not achieved across different groups. The two-year survival rate of all patients was 96.7% (Figure 1A). There was no significant difference in survival rate between male and female patients (two-year survival rate, 95.2% vs. 97.7%, $p = 0.153$, Figure 1B). Patients with ECOG 0 had longer survival than patients with ECOG 1 (two-year survival rate, 100% vs. 92.6%, $p = 0.000$, Figure 1C). Patients with distant metastases had worse survival than those without metastases (two-year survival rate, 84.0% vs. 99.4%, $p = 0.000$, Figure 1D). Furthermore, multivariate analysis revealed that metastasis was an independent adverse prognostic factor for survival (hazard ratio 9.8, $p = 0.000$). A total of 17 cancer patients have died, including nine patients with gastric cancer, three patients with colorectal cancer, three patients with hepatocellular carcinoma, one patient with pancreatic cancer, and one patient with glioma (Table 3). One gastric cancer patient died of immune-related pneumonia, one patient with hepatocellular carcinoma died of upper gastrointestinal hemorrhage, and the other patients died of the end-stage cancers.




Figure 1. Overall survival: A, all 620 young cancer patients; B, female patients vs. male patients; C, patients with ECOG PS 0 (Eastern Cooperative Oncology Group performance status) vs. patients with ECOG PS 1; D, non-metastatic patients vs. metastatic patients.

Table 3. Types of cancer in 17 dead patients.

Type of cancer	Total n=17 (%)
Gastric cancer	9 (52.9)
Colorectal cancer	3 (17.6)
Hepatocellular carcinoma	3 (17.6)
Pancreatic cancer	1 (5.9)
Glioma	1 (5.9)

DISCUSSION

In this retrospective, single-center study, the clinical characteristics, and outcomes of 620 young cancer patients who aged 18-45 years were analyzed over the past two years. The most common types of cancer were thyroid cancer (29.4%), NSCLC (17.1%) and soft tissue sarcoma (14.2%). Univariate and multivariate analyses revealed that distant metastasis was an independent adverse prognostic factor for survival.

Zheng et al¹² reported the incidence and mortality rates of cancer in China in 2016. The most frequent cancer types were lung cancer, colorectal cancer, and gastric cancer. The leading causes of cancer death were lung cancer, liver cancer and stomach cancer. The new cancer cases and deaths in China in 2022 were also reported¹³. The results suggested that the three dominant cancer types and cancer-related deaths remained the same as six years ago. Similar results were obtained when the clinical

features of patients with multiple primary malignancies were retrospectively analyzed¹⁴. Regrettably, no study analyzed the data related to young cancer patients.

Nakata et al¹⁵ concentrated on the epidemiology and survival of cancer in adolescents and young adults in Japan. In male patients, testicular cancer and gastrointestinal cancer were the most common cancer types in cases who aged 25-29 and 30-39 years, respectively. In female patients who aged 20-24, 25-29, 30-34 and 35-39 years, the most common cancer types were thyroid cancer, ovarian cancer, breast cancer and cervical cancer, respectively. The 5-year OS of all cancer patients diagnosed between 2007 and 2011 was 80% for those who aged 15-29 years, and 79% for those who aged 30-39 years. Miller et al¹¹ reported the cancer statistics for young patients in the United States in 2020. The most diagnosed cancer types were thyroid cancer, female breast cancer and melanoma of the skin. The 5-year survival rate was 86% and 83% in patients who aged 20-29 and 30-39 years, respectively. The three leading causes of cancer death among patients who aged 15-39 years were nervous system tumors, leukemia, and colorectal cancer for men, and breast cancer, cervical cancer, and nervous system tumors in women. In the present study, the most common cancer types were thyroid cancer, NSCLC, and soft tissue sarcoma, which was different from the two Chinese studies^{12,13}. However, the two Chinese studies included all age groups, which was different from our young cases. In young cancer patients from Japan¹⁵ and America¹¹, thyroid cancer was identified as the most frequent cancer type. Owing to the advancements in detection methods, a growing number of thyroid cancer cases could be diagnosed at an early stage. Additionally, in the present study, all thyroid cancer patients had papillary carcinoma, which was associated with a very favorable prognosis.

The 2-year survival rate of all young cancer patients was 96.7%, which was remarkably higher than the 5-year survival rate reported in studies from Japan and America, ranging from 79% to 86%^{11,15}. However, the follow-up time in the present study was significantly shorter, and hematological malignancies with poor outcomes were also excluded from this study, thus, the survival rates need to be further confirmed with the extension of follow-up time in the future research.

Good ECOG PS of cancer patients are associated with favorable prognostic outcomes^{16,17}. In the present study, patients with ECOG 0 had a better survival than those with ECOG 1. However, the survival advantage was not preserved after multivariate analysis. Patient with ECOG ≤ 1 mainly receive the treatment of the same intensity, which may explain the result.

Distant metastases frequently indicate unfavorable outcomes in cancer patients¹⁸⁻²⁰. This was also confirmed in the present research. Metastasis was found as the only independent adverse prognostic factor for survival. Therefore, early diagnosis and timely treatment before cancer metastases are of vital importance for the survival of the disease. In the US, the greatest number of cancer-related deaths were attributed to lung cancer, colorectal cancer, and pancreatic cancer among patients of all ages. In patients who aged 20-39 years, the three leading causes of cancer death were breast cancer, colorectal cancer and nervous system tumors¹⁰. Although thyroid cancer, NSCLC, soft tissue sarcoma and breast cancer were found as the most common cancer types in the present study, these cancer types can be detected in early-stages through self-examination or regular physical examination. In addition, for NSCLC and breast cancer, there are multiple and rapidly advancing treatment options. Therefore, none of these patients died in the current study. On the contrary, among the 17 deceased patients, 16 were diagnosed as gastrointestinal cancer, particularly gastric cancer. Young individuals often neglect digestive symptoms, and effective screening, such as gastroscopy, are not routinely employed in this population. Consequently, they are frequently diagnosed at an advanced stage, posing challenges for effective treatment, leading to rapid progression due to a lack of sustained and effective intervention^{21,22}.

The present study included two limitations. Firstly, the therapeutic outcomes and prognosis vary among different cancer types. In this study, the survival data were not specific to a certain cancer, and the outcome of a specific young-onset cancer remained to be clarified. Secondly, data from young cancer patients were collected over the recent two years. Despite prioritizing timely results, the relatively short follow-up time might lead to deviation in survival rates.

CONCLUSIONS

In young cancer patients, thyroid cancer, NSCLC, and soft tissue sarcoma were found as the most common cancer types. In contrast, the top fatal cancer types were mainly digestive cancers, such as gastric cancer and colorectal cancer. Metastasis was noted as an independent unfavorable prognostic factor for survival. Therefore, regular screening and timely diagnosis before metastasis are crucial to the therapy of young cancer patients.

FUNDING:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

AUTHORS' CONTRIBUTIONS:

Wang XK collected the data and drafted the manuscript; Wu Y analyzed the data, and drafted the manuscript; Zhou MH performed the study design, analyzed the data and revised the manuscript. All the authors read and approved the final manuscript.

ORCID ID:

Min-hang Zhou: <https://orcid.org/0000-0002-2094-4127>

CONFLICTS OF INTEREST:

The authors declare that there is no conflict of interest.

ETHICS APPROVAL AND INFORMED CONSENT STATEMENT:

This study was approved by the institutional review board of Chinese PLA General Hospital. Written informed consent was not required because of retrospective method and anonymous data.

DATA AVAILABILITY STATEMENT:

The data used to support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

1. Tricoli JV, Blair DG, Anders CK, Bleyer WA, Boardman LA, Khan J, Kummar S, Hayes-Lattin B, Hunger SP, Merchant M, Seibel NL, Thurin M, Willman CL. Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma. *Cancer* 2016; 122: 1017-1028.
2. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The distinctive biology of cancer in adolescents and young adults. *Nat Rev Cancer* 2008; 8: 288-298.
3. Kumar R, Abreu C, Toi M, Saini S, Casimiro S, Arora A, Paul AM, Velaga R, Rameshwar P, Lipton A, Gupta S, Costa L. Oncobiology and treatment of breast cancer in young women. *Cancer Metastasis Rev* 2022; 41: 749-770.
4. Liu L, Moke DJ, Tsai KY, Hwang A, Freyer DR, Hamilton AS, Zhang J, Cockburn M, Deapen D. A Reappraisal of Sex-Specific Cancer Survival Trends Among Adolescents and Young Adults in the United States. *J Natl Cancer Inst* 2019; 111: 509-518.
5. Spaander MCW, Zauber AG, Syngal S, Blaser MJ, Sung JJ, You YN, Kuipers EJ. Young-onset colorectal cancer. *Nat Rev Dis Primers* 2023; 9: 21.
6. Bryant H. Screening for cancer in children, adolescents, and young adults: questions--and more questions. *Cancer* 2011; 117: 2275-2280.
7. Ariake K, Unno M, Yoshida H, Kubo S, Horiguchi A, Yamaue H, Yamamoto M. Risk factors and characteristics of young patients with the biliary tract carcinoma: results of a project study for biliary surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. *J Hepatobiliary Pancreat Sci* 2020; 27: 571-580.
8. Luen SJ, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperis A, Brown LC, Láng I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Müller B, Jochum W, Bonnefoi H, Martino S, Davidson NE, Geyer C, Chia SK, Ingle JN, Coleman R, Solbach C, Thürlimann B, Colleoni M, Coates AS, Goldhirsch A, Fleming GF, Francis PA, Speed TP, Regan MM, Loi S. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. *Ann Oncol* 2023; 34: 397-409.
9. Berkman AM, Mittal N, Roth ME. Adolescent and young adult cancers: unmet needs and closing the gaps. *Curr Opin Pediatr* 2023; 35: 84-90.
10. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA Cancer J Clin* 2023; 73: 17-48.
11. Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL. Cancer statistics for adolescents and young adults, 2020. *CA Cancer J Clin* 2020; 70: 443-459.
12. Zheng RS, Zhang SW, Sun KX, Chen R, Wang SM, Li L, Zeng HM, Wei WW, He J. [Cancer statistics in China, 2016]. *Zhonghua Zhong Liu Za Zhi* 2023; 45: 212-220.
13. Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. *Chin Med J (Engl)* 2022; 135: 584-590.
14. Wang XK, Zhou MH. Clinical features and survival of patients with multiple primary malignancies. *World J Clin Cases* 2021; 9: 10484-10493.
15. Nakata K, Hiyama E, Katanoda K, Matsuda T, Tada Y, Inoue M, Kawa K, Maru M, Shimizu C, Horibe K, Miyashiro I. Cancer in adolescents and young adults in Japan: epidemiology and cancer strategy. *Int J Clin Oncol* 2022; 27: 7-15.
16. Eismann L, Bohn L, Buchner A, Casuscelli J, Volz Y, Weinhold P, Wülfing C, Waidelich R, Stief CG, Schlenker B, Rodler S. Age and ECOG Performance Status as Predictors of Survival of Patients with Upper Urinary Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy. *Urol Int* 2023; 107: 72-79.
17. da Silva SHK, de Oliveira LC, MSDM ESL, Wiegert EVM, Motta RST, Ferreira Peres WA. The patient generated-subjective global assessment (PG-SGA) and ECOG performance status are associated with mortality in patients hospitalized with breast cancer. *Clin Nutr ESPEN* 2023; 53: 87-92.
18. Zhang W, Wu S, Liu J, Zhang X, Ma X, Yang C, Cao M, Zhang S, Liu Y. Metastasis patterns and prognosis in young breast cancer patients: A SEER database analysis. *Front Oncol* 2022; 12: 872862.
19. Weller JH, Westermann C, Patel P, Beckman RM, Pratilas CA, Morris CD, Rhee DS: Trends of lymph node sampling and metastasis in pediatric and young adult patients with clear cell, epithelioid, and synovial sarcomas. *Pediatr Blood Cancer* 2022; 69: e29455.

20. Zhou MH, Wu Y, Sun JZ. Clinical features and prognostic factors in 190 cancer patients with brain metastases. *Transl Cancer Res* 2020; 9: 1160-1166.
21. Zaborowski AM, Murphy B, Creavin B, Rogers AC, Kennelly R, Hanly A, Martin ST, O'Connell PR, Sheahan K, Winter DC: Clinicopathological features and oncological outcomes of patients with young-onset rectal cancer. *Br J Surg* 2020; 107: 606-612.
22. Hughes N, Stark D. The management of adolescents and young adults with cancer. *Cancer Treat Rev* 2018; 67: 45-53.